Legal & General Group Plc lifted its holdings in shares of Akcea Therapeutics Inc (NASDAQ:AKCA) by 17.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,237 shares of the company’s stock after acquiring an additional 338 shares during the period. Legal & General Group Plc’s holdings in Akcea Therapeutics were worth $79,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Akcea Therapeutics by 6.8% during the second quarter. BlackRock Inc. now owns 1,901,547 shares of the company’s stock worth $45,087,000 after purchasing an additional 121,184 shares during the period. FMR LLC lifted its holdings in shares of Akcea Therapeutics by 24.5% during the second quarter. FMR LLC now owns 12,455,383 shares of the company’s stock worth $295,317,000 after purchasing an additional 2,447,367 shares during the period. Bank of America Corp DE lifted its holdings in shares of Akcea Therapeutics by 79.8% during the second quarter. Bank of America Corp DE now owns 12,368 shares of the company’s stock worth $293,000 after purchasing an additional 5,490 shares during the period. Millennium Management LLC lifted its holdings in shares of Akcea Therapeutics by 428.7% during the second quarter. Millennium Management LLC now owns 63,998 shares of the company’s stock worth $1,517,000 after purchasing an additional 51,894 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Akcea Therapeutics by 7.7% during the second quarter. Northern Trust Corp now owns 184,071 shares of the company’s stock worth $4,364,000 after purchasing an additional 13,147 shares during the period. Institutional investors and hedge funds own 25.95% of the company’s stock.

Shares of NASDAQ AKCA opened at $25.89 on Monday. Akcea Therapeutics Inc has a 1-year low of $15.73 and a 1-year high of $40.75. The firm has a market cap of $2.31 billion, a P/E ratio of -11.56 and a beta of 1.58.

Separately, Zacks Investment Research downgraded Akcea Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $38.20.

ILLEGAL ACTIVITY WARNING: “Legal & General Group Plc Increases Stake in Akcea Therapeutics Inc (AKCA)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2019/02/11/legal-general-group-plc-increases-stake-in-akcea-therapeutics-inc-akca.html.

Akcea Therapeutics Profile

Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.

Featured Story: Calculate Your Return on Investment (ROI)

Institutional Ownership by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.